Covid-19 and gastrointestinal and hepatobiliary diseases

Anita Rao*, Mora Puertolas, Joseph Runde

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Since its initial onset in 2019,severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spread quickly across the globe, resulting in the potentially life-threatening respiratory coronavirus disease 2019 (COVID-19). Although less commonly reported, COVID-19 has also been associated with gastrointestinal and hepatic manifestations, which may occur more frequently in children. This has also led to concern about the susceptibility of children to the SARS-CoV-2 virus who have underlying chronic digestive disease and may be treated with immune suppression. As such, recommendations and expert consensus regarding the management of chronic gastrointestinal and hepatobiliary disease have been of great interest during the pandemic and international database reporting has informed our understanding. The impact of COVID-19 on the gastrointestinal tract and its influence on the management of pediatric digestive disease is reviewed in this article. [Pediatr Ann. 2021;50(8):e315-e319.].

Original languageEnglish (US)
Pages (from-to)e315-e319
JournalPediatric annals
Volume50
Issue number8
DOIs
StatePublished - 2021
Externally publishedYes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint

Dive into the research topics of 'Covid-19 and gastrointestinal and hepatobiliary diseases'. Together they form a unique fingerprint.

Cite this